Approval Is Not Access: The Five Gates Between an FDA Approval and a Patient in California

I have had a version of the same conversation four times in the last two months. It goes like this: psilocybin is about to be approved, so we are getting ready to open. When can we start seeing patients?

The honest answer is that FDA approval is the first of at least five separate legal gates, and in California it is not the one that will hold you up. I want to lay out all five, in order, because the sequencing determines what you should be building now and what you should not be spending money on yet.

Where things actually stand

Compass Pathways is submitting its New Drug Application for COMP360 psilocybin in treatment-resistant depression on a rolling basis. Both Phase 3 trials met their primary endpoints — COMP005 showed a 3.6-point difference on the MADRS depression scale against placebo, and COMP006 showed a 3.8-point difference for the 25 mg dose against a 1 mg comparator, both at p<0.001. In April 2026 the FDA granted the company a rolling review and awarded a Commissioner’s National Priority Voucher, a program the agency describes as compressing review to roughly one to two months after filing.

The company has said it expects to complete the submission in Q4 2026 and, on its August 5, 2026 earnings call, that the FDA “has begun reviewing modules already submitted.” Its own launch target is the first half of 2027 — and management has been careful to say that target is contingent on approval and on federal and state rescheduling.

That last clause is the whole point of this post.

Gate one: FDA approval

The obvious one. Worth noting only that no PDUFA goal date has been publicly announced, which means the widely repeated “approval by the end of the year” timelines are inference, not schedule.

Also worth noting: two other psychedelic programs received priority vouchers in April 2026 — Usona Institute’s psilocybin for major depressive disorder, and the methylone program (TSND-201), an MDMA-type entactogen, for PTSD. And a separate MDMA application for PTSD has reportedly been resubmitted to the FDA, roughly two years after the August 2024 Complete Response Letter. The word reportedly is doing real work there: the resubmission has been described by trade press citing people familiar with the filing, with no sponsor announcement and no FDA acknowledgment behind it. Treat it as unconfirmed rather than as a fixed point in your planning.

Gate two: federal rescheduling

This is the gate people forget, and it is a real one.

Psilocybin is a Schedule I controlled substance under federal law. Schedule I means, by statutory definition, no currently accepted medical use. An FDA approval does not automatically move a substance out of Schedule I — it creates the factual predicate for the DEA to do so, through a separate administrative process.

Executive Order 14401 addresses this directly, directing the Attorney General to initiate and complete review of any Schedule I product that has “successfully completed Phase 3 clinical trials” for serious mental health disorders, so rescheduling may proceed “as quickly as practicable.” That is meaningful language. It is also not a deadline. Multiple law firm analyses of the order have noted that it contains no numerical day-count requirements, and I would not represent to a client that it does.

There is a template for how fast this can move when the executive branch wants it to. In April 2026 the Acting Attorney General placed FDA-approved marijuana products into Schedule III by order, published at 91 Fed. Reg. 22714 and effective April 28, 2026, relying on the Attorney General’s authority under 21 U.S.C. § 811(d)(1). That rule says nothing about psychedelics. But it demonstrates the mechanism, and commentators have reasonably read it as a preview of how a post-approval psilocybin rescheduling would be executed.

Until rescheduling happens, every person who touches the substance — manufacturer, distributor, clinic, prescriber — needs Schedule I registration, and Schedule I registration is not designed for clinical practice.

Gate three: state scheduling

Here is where California becomes its own problem.

Psilocybin and psilocyn are listed in California’s own Schedule I at Health & Safety Code § 11054(d)(18) and (19). California’s schedules are a state statute. A federal rescheduling does not amend them. Someone has to.

Two states have already solved this in advance, and they are worth studying:

Virginia enacted companion bills in 2026 (HB 1347 and SB 379) requiring the Board of Pharmacy to reschedule an FDA-approved, professionally administered psilocybin formulation at its next quarterly meeting following the expiration of 30 days from Federal Register publication of the federal scheduling order.
South Dakota enacted HB 1099, signed March 10, 2026, conditionally legalizing crystalline polymorph psilocybin for mental health therapy — effective only upon both FDA approval and DEA rescheduling out of Schedule I.

California has enacted no such trigger. SB 58, which would have decriminalized possession of psilocybin, psilocyn, DMT and mescaline for adults 21 and over, was vetoed on October 7, 2023. SB 1012, which would have built an actual regulated facilitator and therapy framework, was held in Senate Appropriations on May 16, 2024 and died there. Nothing has replaced either one.

So the realistic California sequence is: federal approval, federal rescheduling, then a state legislative or administrative fix that does not yet exist. That is not a short runway.

Gate four: the conditions on the approval itself

Assume all three gates above clear. You still cannot administer the drug however you like.

The FDA’s July 2026 final guidance on psychedelic clinical investigations contemplates two monitors present for the duration of a treatment session, with a lead monitor who is an independently licensed health care provider with graduate-level psychotherapy training. It recommends blinded long-term follow-up, typically twelve months, with prespecified retreatment criteria. It notes the agency anticipates that additional safety assessment may be needed in the postmarketing setting.

Those are trial standards. But the post-approval analogue is a REMS — a Risk Evaluation and Mitigation Strategy — and a REMS can require certified prescribers, certified sites, patient enrollment, and mandatory monitoring intervals. Compass has said labeling and REMS discussions are expected later in its review.

If you are designing a facility right now, design it for two clinicians in the room and a long session tail. If a lighter standard emerges, you will have overbuilt slightly. If you build for one clinician and a heavier standard emerges, you will have built something you cannot use.

Gate five: California’s structural law — and this one you can work on today

This is the gate you actually control, and it is the reason I tell people to stop waiting.

California’s corporate practice of medicine doctrine holds that a lay corporation cannot practice medicine or employ physicians to deliver professional services. Business & Professions Code § 2400 states it flatly: “Corporations and other artificial legal entities shall have no professional rights, privileges, or powers.” Unlicensed practice is reached by § 2052; fee-splitting and referral compensation by § 650.

For a long stretch, this doctrine lived mostly in case law and Medical Board guidance. That changed. SB 351, Chapter 409 of the Statutes of 2025, was signed October 6, 2025 and took effect January 1, 2026. It adds Division 1.7 (commencing with § 1190) to the Health & Safety Code, codifying the doctrine and aiming it squarely at private equity and hedge fund involvement in physician and dental practices.

Under SB 351, a lay entity may not control hiring and firing based on clinical competency, coding and billing decisions, medical equipment selection, patient records, diagnostic testing decisions, referrals, patient volume, or provider hours. It also voids contract clauses that bar a provider from competing after termination, or from disparaging or commenting on patient care and ethical or professional concerns. Enforcement runs through the Attorney General, by injunction and other equitable relief, and offending provisions are void and unenforceable as against public policy.

The Medical Board’s own published guidance identifies the same territory — that the physician must retain responsibility for the ultimate overall care of the patient, and that decisions like ownership of patient records, clinical staff hiring, payer contracting parameters, and coding and billing are not for a lay entity to control.

If your management services organization agreement was papered before 2026, it was drafted against a different statute than the one now in force. That is a document review you can do this month, at a known cost, with a known benefit — and it is entirely independent of whether the FDA approves anything.

What I would build now, and what I would not

Build now: entity structure and MSO agreements that survive SB 351. Clinical governance documentation. Credentialing standards you can defend. Screening and informed consent protocols. Adverse event definitions and reporting. Records architecture. Relationships with a Schedule I-capable pharmacy partner. A considered answer to the questions federal agencies are already asking about training, credentialing and staffing.

Do not build yet: physical capacity sized to an approval date nobody has announced. Marketing that implies availability. Anything that depends on Right to Try access, which does not currently exist as an implemented pathway. Anything that treats a local decriminalization resolution as legal cover — which I have covered separately, and which is the single most common misunderstanding I encounter.

Deja A. Correia, Esq. | The Correia Law Firm | San Diego, California

This post is general information about publicly available legal and regulatory developments. It is not legal advice, it does not create an attorney-client relationship, and it should not be relied on as a substitute for advice about your specific situation. Statutory and regulatory status in this area is changing quickly; verify current status before acting.